Glenmark Pharmaceuticals gets tentative approval of Saxagliptin Tablets

From USFDA

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca AB.

According to IMS Health sales data for the 12 month period ending April 2017, the Onglyza Tablets, 2.5 mg and 5 mg market1 achieved annual sales of approximately $518.5 million.

Powered by Capital Market - Live News